Efficacy and safety of adalimumab as the first- and second-line biologic therapy for children with juvenile idiopathic arthritis under four years of age
Titel:
Efficacy and safety of adalimumab as the first- and second-line biologic therapy for children with juvenile idiopathic arthritis under four years of age
Auteur:
Alexeeva, Ekaterina Dvoryakovskaya, Tatyana Denisova, Rina Sleptsova, Tatyana Isaeva, Kseniya Chomahidze, Alexandra Fetisova, Anna Mamutova, Anna Alshevskaya, Alina Moskalev, Andrey